Altre lingue Allergy Therapeutics plc

Azioni

AGY

GB00B02LCQ05

Mercato chiuso - London S.E. Altri mercati azionari 17:35:05 21/06/2024			Variaz. 5gg	Var. 1 gen.
5,25 ^GBX	0,00%		0,00%	+110,00%

10/06	VINCITORI E PERDENTI DELLO SCOPO: Arecor Therapeutics crolla per esigenze di finanziamento	AN
10/06	Allergy Therapeutics accoglie con favore i risultati della sperimentazione del vaccino contro l'allergia alle arachidi	AN

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	10/06
Allergy Therapeutics welcomes peanut allergy vaccine trial results	10/06
Abingdon Health buys IVDeology Holdings	07/05
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	07/05
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	03/04
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	27/03
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	27/03
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	27/03
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	27/03
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	27/03
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	27/03
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	27/03
Allergy Therapeutics starts dosing patients in peanut allergy trial	12/03
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	12/03
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	11/03
Allergy Therapeutics forecasts revenue drop but trials going well	14/02
Alliance Pharma appoints chair; FireAngel sales down	05/02
Scancell's Chief Development Officer to Step Down	05/02
Allergy Therapeutics plc - Publication of Annual Report and Accounts 2023	31/01
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	30/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Allergy Therapeutics plc

Azioni

AGY

GB00B02LCQ05

Altre lingue

Filtri